Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETALS study
2013-004974-82Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Feb 2014
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Nilotinib with Nilotinib + peginterferon alfa-2a (2 arms). Primary endpoint: Cumulative MR4.5 rate at 12 months confirmed at 15 months. Started Feb 2014; status: completed.
02
Drugs
nilotinibpeginterferon alfa-2a
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2013-004974-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004974-82.